

Supplementary Materials

Super-enhancer inhibitors THZ2 and JQ1 reverse temozolomide resistance in glioblastoma by suppressing SE-driven SOX9 expression

**Xinqi Teng^{1,2,#}, Yiming Wang^{1,#}, Qiang Qu^{3,4,#}, Weixin Xu¹, Haihui Zhuang¹,
Yiwen Wei¹, Yinghuan Dai⁵, Jian Qu^{1,6}**

¹Department of Pharmacy, the Second Xiangya Hospital, Central South University; Institute of Clinical Pharmacy, Central South University, Changsha 410011, Hunan, China.

²Department of Pharmacy, Wuhan No.1 Hospital (Wuhan Integrated TCM & Western Medicine Hospital), Wuhan 430022, Hubei, China.

³Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China.


⁴National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China.

⁵Department of Pathology, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China.

⁶Hunan key laboratory of the research and development of novel pharmaceutical preparations, Changsha Medical University, Changsha 410219, Hunan, China.

[#]Authors contributed equally.

Correspondence to: Dr. Jian Qu, Department of Pharmacy, the Second Xiangya Hospital, Central South University; Institute of Clinical Pharmacy, Central South University, No.139 Middle Renmin Road, Changsha 410011, Hunan, China. E-mail: qujianstanley@csu.edu.cn



Supplementary Figure 1. JQ1 suppresses GBM cell viability. The IC₅₀ of JQ1 on 4 GBM cell lines. Data represent the mean \pm SD ($n = 3$).